4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Sleep Apnea Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Sleep Apnea by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 87 ongoing clinical trials involving Sleep Apnea
Of the 87 trials,33 trials are in Phase II
Furthermore, 29 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Sleep Apnea by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Sleep Apnea, a respiratory condition. The largest number of ongoing clinical trials for Sleep Apnea is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Sleep Apnea-related drug trials.

Brigham and Women's Hospital: The leading ongoing Sleep Apnea related clinical trial sponsor

Brigham and Women's Hospital is the top sponsor for Sleep Apnea-related ongoing clinical trials.

Apnimed Inc, VA Office of Research and Development, University Hospital Antwerp, Shionogi & Co Ltd, and Eisai Co Ltd are among other notable clinical trial sponsors involved in Sleep Apnea. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Sleep Apnea

Pitolisant hydrochloride (Wakix, Ozawade), Solriamfetol hydrochloride (Sunosi), and Modafinil (Provigil, Modiodal, Vigil, and Alertec) are key marketed drugs involving Sleep Apnea.

Pitolisant hydrochloride (Wakix, Ozawade) is a central nervous system drug. It functions via Histamine H3 Receptor Antagonist mechanism of action. It is formulated as film-coated tablets for oral route of administration. Wakix is indicated in adults for the treatment of narcolepsy with or without cataplexy. Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). Pitolisant hydrochloride was first approved in 2016 and is marketed globally including in the US, the UK, France, and Germany by Harmony Biosciences Holdings Inc.

Solriamfetol hydrochloride (Sunosi) was a phenylalanine derivative, acts as a wake-promoting agent. It functions via Sodium Dependent Dopamine Transporter Inhibitor, Sodium Dependent Noradrenaline Transporter Inhibitor mechanism of action. It is formulated as film-coated tablets for oral route of administration. Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA), and to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). Solriamfetol hydrochloride was first approved in 2019 and is marketed globally including in the US, the UK, France, and Germany by Jazz Pharmaceuticals Inc.

Explore the latest trends and actionable insights on the Sleep Apnea Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Sleep Apnea Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store